Category News

WuXi Biologics

WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership

WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Advancements in Bioprocessing, Manufacturing Quality, and Digital Innovation WuXi Biologics a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced…

Read MoreWuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership
Parabilis

Parabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumor Treatment

Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical…

Read MoreParabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumor Treatment